Northern Trust’s Context Therapeutics CNTX Stock Holding History

Northern Trust’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$341K	Buy	615,576 +512,320	+496%	+$1.04M	﹤0.01%	3768
2026 Q1	$271K	Buy	103,256 +18,975	+23%	+$44.3K	﹤0.01%	3844
2025 Q4	$124K	Buy	84,281 +17,897	+27%	+$20.9K	﹤0.01%	4092
2025 Q3	$64.3K	Sell	66,384 -47,181	-42%	-$38.2K	﹤0.01%	4231
2025 Q2	$74.4K	Hold	113,565	–	–	﹤0.01%	4170
2025 Q1	$69.5K	Hold	113,565	–	–	﹤0.01%	4181
2024 Q4	$119K	Sell	113,565 -58,946	-34%	-$102K	﹤0.01%	4121
2024 Q3	$338K	Sell	172,511 -1,986	-1%	-$4.41K	﹤0.01%	3696
2024 Q2	$350K	Buy	174,497 +137,278	+369%	+$237K	﹤0.01%	3637
2024 Q1	$51.4K	Hold	37,219	–	–	﹤0.01%	4223
2023 Q4	$42.1K	Hold	37,219	–	–	﹤0.01%	4262
2023 Q3	$56.2K	Hold	37,219	–	–	﹤0.01%	4139
2023 Q2	$59.5K	Hold	37,219	–	–	﹤0.01%	4174
2023 Q1	$20.9K	Hold	37,219	–	–	﹤0.01%	4441
2022 Q4	$24.3K	Buy	37,219 +14,019	+60%	+$15.1K	﹤0.01%	4448
2022 Q3	$26K	Hold	23,200	–	–	﹤0.01%	4496
2022 Q2	$49K	Buy	+23,200	New	+$43.5K	﹤0.01%	4413

Other funds holding CNTX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust's CNTX Position: Q2 2026 in Review

Northern Trust increased its Context Therapeutics (CNTX) stake by 496% in Q2 2026, buying an estimated $1.04M and bringing the position to 615,576 shares worth $341K. The position accounts for ﹤0.01% of the portfolio, ranked #3768.

Northern Trust first reported a position in CNTX in Q2 2022 and has held it in 17 quarters since. The position peaked at $350K in Q2 2024. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Northern Trust held 615,576 shares of Context Therapeutics worth $341K as of Q2 2026.
Northern Trust bought 512,320 Context Therapeutics shares in Q2 2026, an estimated $1.04M.
Context Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3768 holding.
Northern Trust first reported a position in Context Therapeutics in Q2 2022 and has held it in 17 quarters since.
Northern Trust's Context Therapeutics position peaked at $350K in Q2 2024.
43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.